D. Kalra

SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network.

BACKGROUND AND AIM Fabry disease (FD) is frequently complicated by renal impairment and cardiovascular events; however, evidence on sodium-glucose cotransporter-2 inhibitors (SGLT2i) in this population is scarce. Accordingly, we assessed the association between SGLT2i exposure and cardiovascular outcomes in adults with...

Finerenone in Heart Failure with Preserved Ejection Fraction: Expanding the Role of Non-steroidal Mineralocorticoid Receptor Antagonists

Joint associations of Interleukin-6 and apolipoprotein B with major adverse cardiovascular events in the UK biobank.

AIMS The relative contributions of inflammatory and atherogenic lipoprotein pathways to residual cardiovascular risk remain unclear. We examined the joint and independent associations of interleukin-6 (IL-6) and apolipoprotein B (ApoB) with major adverse cardiovascular events (MACE) and mortality. METHODS Among 34,06...